# CYCLOOXYGENASE PRODUCTS & MAMMARY CANCER

> **NIH NIH R01** · BARBARA ANN KARMANOS CANCER INSTITUTE · 1988 · $147,138

## Abstract

The long term objective of this proposal is to study the role of
cyclooxygenase prducts of arachidonic acid metabolism in tumor
growth and metastasis.  For these studies, a murine model of
mammary adenocarcinoma will be used.  Despite intensive study,
the factors that control the growth of breast cancer cells are
poorly understood.  Prostaglandins, the major products of
cyclooxygenase metabolism, are synthesized in abnormally high
levels by breast cancer cells and contribute to the progressive
growth of these lesions.  Clinically, the most difficult problem in
the management of breast cancer is the occurrence of metastasis
and, again, prostaglandins contribute to this poorly understood
process.

The specific aims of this proposal are (1) to elucidate the
mechanisms by which cyclooxygenase products interact with
immune effector cells in the control of primary tumor growth, (2)
to identify the mechanisms by which cyclooxygenase products
interact with immune effector cells in the control of tumor
metastasis and (3) to expand the characterization of prostaglandin
binding to mammary tumor cells and normal mammary epithelium
and to determine the functional significance of the heterogeneity
of binding to different tumor lines.  These studies will be carried
out using a series of murine mammary tumor cell lines that were
originally derived from one spontaneously occurring mammary
tumor.  These closely related lines differ in many properties
including tumorigenicity, immunogenicity, metastatic potential
and prostaglandin synthetic activity.  We will manipulate the
immunologic system and prostaglandin metabolism to define the
role of each factor and to describe the interactions that affect
tumor growth and metastasis. This proposal requires both in vivo
and in vitro studies of immune effector function.  Studies of
prostaglandin binding in vitro require cultured mammary tumor
cells.

## Key facts

- **NIH application ID:** 3175894
- **Project number:** 2R01CA037943-04
- **Recipient organization:** BARBARA ANN KARMANOS CANCER INSTITUTE
- **SAM.gov UEI:** NAJZPZ4GN5B3
- **Principal Investigator:** Amy M. Fulton
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1988
- **Award amount:** $147,138
- **Award type:** 2
- **Project period:** 1988-02-05 → 1989-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3175894

## Citation

> US National Institutes of Health, RePORTER application 3175894, CYCLOOXYGENASE PRODUCTS & MAMMARY CANCER (2R01CA037943-04). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3175894. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*